Abstract
Purpose: Regenerative medicine increasingly focuses on blood-derived products for osteoarthritis therapy. Frequently, citrate-anti-coagulated platelet-rich plasma (CPRP) is intra-articularly injected into diseased joints, however, cell-free alternatives such as hyperacute serum (hypACT) are under development. Mechanisms of action of blood products are still poorly understood. The discovery of extracellular vesicles (EVs) in blood and EV-associated cargo molecules such as miRNAs opened up new levels of complexity in understanding the therapeutic potential of blood products.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
